Symposium speakers
The evolving world of PAP therapy
At our recent symposium, three leading sleep experts explored how shifting demographics are reshaping positive airway pressure (PAP) therapy.
Their conversation spanned technology adaption, innovation and the evolving expectations of treating obstructive sleep apnea (OSA).
Dr. David Rapoport, MD
Director of Research in Integrative Sleep Medicine at the Icahn School of Medicine at Mount Sinai.
Dr. Sairam Parthasarathy, MD
Professor and Director of the University of Arizona Health Sciences Centre for Sleep, Circadian, and Neuroscience Research.
Dr. Joseph Ojile, MD
Founder and CEO of the Clayton Sleep Institute.
Dr. David Rapoport, (MD)
How are patients changing?
Dr Rapoport explores the complexities of sleep apnea and what healthcare providers can expect in the future, including:
- The connection between obesity and OSA.
- How weight loss might impact on the future prevalence of sleep apnea.
- Why sleep apnea won’t disappear, even with treatments such as GLP-1s.
Dr. Sairam Parthasarathy, (MD)
GLP-1s and sleep apnea
Medications are changing the way we approach OSA. Dr. Parthasarathy explains their growing role and impact on therapy.
- Increased use of GLP-1s in OSA treatment.
- Medicine-related facial changes affecting PAP mask fit.
Dr. Joseph Ojile, (MD)
Managing equipment
Dr. Ojile challenges healthcare providers to rethink how they manage OSA treatment as patient profiles and technology change:
- Sleep medicine is evolving, but are treatment strategies keeping up?
- Key considerations for navigating OSA’s changing clinical landscape.
- Why prescribing OSA treatments need a fresh perspective.